Mandate

Vinge has acted for NatWest Markets N.V. in connection with an increase of existing securitisation

October 19, 2022

Vinge has acted for NatWest Markets N.V. as senior noteholder in connection with an amendment and restatement of the existing note facilities agreement with DBT Capital AB as originator and its subsidiary as issuer (jointly “DBT”). The amendment and restatement included, among other things, an increase of the aggregate amount of the facilities to up to SEK 3,100,000,000 and an introduction of an entity controlled by global investment firm Värde Partners as a mezzanine noteholder. The financing is part of a securitisation of secured loans to small and medium sized enterprises (SMEs) originated by DBT.

DBT is a Swedish private lender registered with the Swedish Financial Supervisory Authority and who offers corporate loans and financing to SMEs in Sweden.

The transaction is executed and reported under the EU securitisation regulation (Regulation (EU) 2017/2402 of the European Parliament and of the Council of 12 December 2017) and is subject to the reporting requirements thereunder.

Vinge’s team consisted primarily of responsible partner Albert Wållgren together with associates Seyran Sahin, Axel Jansson, Ulf Pyk and Calle Tengwall Pagels.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025